Reddy⃰ et al. - Google Patents
DEVELOPMENT AND CHARACTERISATION OF GLICLAZIDE COCRYSTALSReddy⃰ et al.
View PDF- Document ID
- 13756967146031356063
- Author
- Reddy⃰ M
- Anusha P
External Links
Snippet
Poor dissolution rate, solubility, chemical stability and moisture uptake influence therapeutic efficacy of many pharmaceuticals, and significantly lower the market value of a drug. A solid can exist in two forms viz. either amorphous or crystalline1. Solid dosage forms are by far the …
- 238000011161 development 0 title abstract description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Izutsu et al. | Characterization and quality control of pharmaceutical cocrystals | |
| Darwish et al. | A new 1: 1 drug-drug cocrystal of theophylline and aspirin: discovery, characterization, and construction of ternary phase diagrams | |
| Hossain Mithu et al. | Advanced methodologies for pharmaceutical salt synthesis | |
| Felix-Sonda et al. | Nitazoxanide cocrystals in combination with succinic, glutaric, and 2, 5-dihydroxybenzoic acid | |
| CN102015696A (en) | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol | |
| Sevukarajan et al. | Synthesis and characterization of a pharmaceutical co-crystal:(aceclofenac: nicotinamide) | |
| Arenas-García et al. | Interrelation of the dissolution behavior and solid-state features of acetazolamide cocrystals | |
| Zhou et al. | Co-crystal formation based on structural matching | |
| Yadav et al. | Cocrystals: A complete review on conventional and novel methods of its formation and its evaluation | |
| Spinelli et al. | Molecular salts of the antidepressant venlafaxine: an effective route to solubility properties modifications | |
| MacEachern et al. | Transformation under pressure: Discovery of a novel crystalline form of anthelmintic drug Praziquantel using high-pressure supercritical carbon dioxide | |
| Mellah et al. | New Cocrystallization Method: Non-photochemical Laser-Induced Nucleation of a Cocrystal of Caffeine–Gallic Acid in Water | |
| Kaviani et al. | Chiral resolution methods for racemic pharmaceuticals based on cocrystal formation | |
| JP7252417B2 (en) | Benzopyrazole Compounds as RHO Kinase Inhibitors, Salt Forms, Crystal Forms and Methods of Making Same | |
| Reddy⃰ et al. | DEVELOPMENT AND CHARACTERISATION OF GLICLAZIDE COCRYSTALS | |
| Shaikh et al. | Novel crystal forms of Entresto: a supramolecular complex of trisodium sacubitril/valsartan hemi-pentahydrate | |
| JP2013528213A (en) | Ezathiostat tablet formulation | |
| Chai et al. | Structural analysis and properties of two novel pharmaceutical salts of letermovir | |
| Kendall et al. | An industrial perspective on co-crystals: Screening, identification and development of the less utilised solid form in drug discovery and development | |
| Reis et al. | Crystallization of isoniazid in choline-based ionic liquids: Physicochemical properties and anti-tuberculosis activity | |
| Li et al. | The discovery of new cocrystals of 5-fluorocytosine using amine–carboxylate supramolecular synthon | |
| Newman et al. | Form selection of pharmaceutical compounds | |
| Dall'Olio | Survey of methodologies of pharmaceutical interest for quantification of crystal form via X-Ray Powder Diffraction | |
| Dontulwar et al. | Green approach towards Synthesis and structural analysis of benzocaine-based compound and its co-crystals | |
| Bhattacharyya et al. | A comprehensive review on pharmaceutical cocrystal-a subtle technique for solubility enhancement. |